Summary
Conventionally, antibody phage display has been used to isolate recombinant antibodies that are monovalent in their interaction with target antigens. These antibodies can be reengineered for expression in mammalian cell culture as full-length, monospecific immunoglobulins. An emerging branch of research has sought to generate bivalent recombinant antibodies by manipulating the length of the linker separating heavy- and light-chain variable domains in single-chain Fv proteins, thereby promoting inter-scFv interaction and the formation of “diabodies.” With careful control, this can generate scFv-based proteins able to bind two very distinct targets, “bispecific diabodies.” Further manipulation enables the assembly of higher-order complexes.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Bird, R. E., Hardman, K. D., Jacobson, J. W., Johnson, S., Kaufman, B. M., Lee, S. M., Lee, T., Pope, S. H., Riordan, G. S., and Whitlow, M. (1988) Single-chain antigen-binding proteins. Science 242, 423–426.
Huston, J. S., Levinson, D., Mudgett Hunter, M., Tai, M. S., Novotny, J., Margolies, M. N., Ridge, R. J., Bruccoleri, R. E., Haber, E., Crea, R., and Oppermann, H. (1988) Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc. Natl. Acad. Sci. USA 85, 5879–5883.
Milenic, D. E., Yokota, T., Filpula, D. R., Finkelman, M. A., Dodd, S. W., Wood, J. F., Whitlow, M., Snoy, P., and Schlom, J. (1991) Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res. 51, 6363–6371.
Yokota, T., Milenic, D. E., Whitlow, M., and Schlom, J. (1992) Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res. 52, 3402–3408.
Yokota, T., Milenic, D. E., Whitlow, M., Wood, J. F., Hubert, S. L., and Schlom, J. (1993) Microautoradiographic analysis of the normal organ distribution of radioiodinated single-chain Fv and other immunoglobulin forms. Cancer Res. 53, 3776–3783.
Adams, G. P., McCartney, J. E., Tai, M. S., Oppermann, H., Huston, J. S., Stafford, W. F., Bookman, M. A., Fand, I., Houston, L. L., and Weiner, L. M. (1993) Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv. Cancer Res. 53, 4026–4034.
Borsi, L., Balza, E., Bestagno, M., Castellani, P., Carnemolla, B., Biro, A., Leprini, A., Sepulveda, J., Burrone, O., Neri, D., and Zardi, L. (2002) Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int. J. Cancer 102, 75–85.
Holliger, P., Prospero, T., and Winter, G. (1993) “Diabodies”: small bivalent and bispecific antibody fragments. Proc. Natl. Acad. Sci. USA 90, 6444–6448.
Adams, G. P., Schier, R., McCall, A. M., Crawford, R. S., Wolf, E. J., Weiner, L. M., and Marks, J. D. (1998) Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. Br. J. Cancer 77, 1405–1412.
Viti, F., Tarli, L., Giovannoni, L., Zardi, L., and Neri, D. (1999) Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis. Cancer Res. 59, 347–352.
Kipriyanov, S. M., and Le Gall, F. (2004) Generation and production of engineered antibodies. Mol. Biotechnol. 26, 39–60.
Lu, D., Jimenez, X., Witte, L., and Zhu, Z. (2004) The effect of variable domain orientation and arrangement on the antigen-binding activity of a recombinant human bispecific diabody. Biochem. Biophys. Res. Commun. 318, 507–513.
Perisic, O., Webb, P. A., Holliger, P., Winter, G., and Williams, R. L. (1994) Crystal structure of a diabody, a bivalent antibody fragment. Structure 2, 1217–1226.
Carmichael, J. A., Power, B. E., Garrett, T. P., Yazaki, P. J., Shively, J. E., Raubischek, A. A., Wu, A. M., and Hudson, P. J. (2003) The crystal structure of an anti-CEA scFv diabody assembled from T84.66 scFvs in VL-to-VH orientation: implications for diabody flexibility. J. Mol. Biol. 326, 341–351.
Zhu, Z., Zapata, G., Shalaby, R., Snedecor, B., Chen, H., and Carter, P. (1996) High level secretion of a humanized bispecific diabody from Escherichia coli. Biotechnology (NY) 14, 192–196.
Cochlovius, B., Kipriyanov, S. M., Stassar, M. J., Christ, O., Schuhmacher, J., Strauss, G., Moldenhauer, G., and Little, M. (2000) Treatment of human B cell lymphoma xenografts with a CD3 x CD19 diabody and T cells. J. Immunol. 165, 888–895.
Holliger, P., Brissinck, J., Williams, R. L., Thielemans, K., and Winter, G. (1996) Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody. Protein Eng. 9, 299–305.
Kipriyanov, S. M., Moldenhauer, G., Strauss, G., and Little, M. (1998) Bispecific CD3 x CD19 diabody for T cell-mediated lysis of malignant human B cells. Int. J. Cancer 77, 763–772.
Arndt, M. A., Krauss, J., Kipriyanov, S. M., Pfreundschuh, M., and Little, M. (1999) A bispecific diabody that mediates natural killer cell cytotoxicity against xenotransplanted human Hodgkin’s tumors. Blood 94, 2562–2568.
Kipriyanov, S. M., Cochlovius, B., Schäfer, H. J., Moldenhauer, G., Bähre, A., Le Gall, F., Knackmuss, S., and Little, M. (2002) Synergistic antitumor effect of bispecific CD19 x CD3 and CD19 x CD16 diabodies in a preclinical model of non-Hodgkin’s lymphoma. J. Immunol. 169, 137–144.
Schlenzka, J., Moehler, T. M., Kipriyanov, S. M., Kornacker, M., Benner, A., Bähre, A., Stassar, M. J., Schäfer, H. J., Little, M., Goldschmidt, H., and Cochlovius, B. (2004) Combined effect of recombinant CD19 x CD16 diabody and thalidomide in a preclinical model of human B cell lymphoma. Anticancer Drugs 15, 915–919.
Houtenbos, I., Santegoets, S., Westers, T. M., Waisfisz, Q., Kipriyanov, S., Denkers, F., Scheper, R. J., de Gruijl, T. D., Ossenkoppele, G. J., and van de Loosdrecht, A. A. (2008) The novel bispecific diabody αCD40/αCD28 strengthens leukaemic dendritic cell-induced T-cell reactivity. Br. J. Haematol. in press.
Kipriyanov, S. M., Moldenhauer, G., Schuhmacher, J., Cochlovius, B., Von der Lieth, C. W., Matys, E. R., and Little, M. (1999) Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics. J. Mol. Biol. 293, 41–56.
Kipriyanov, S. M., Moldenhauer, G., Braunagel, M., Reusch, U., Cochlovius, B., Le Gall, F., Kouprianova, O. A., Von der Lieth, C. W., and Little, M. (2003) Effect of domain order on the activity of bacterially produced bispecific single-chain Fv antibodies. J. Mol. Biol. 330, 99–111.
Le Gall, F., Reusch, U., Little, M., and Kipriyanov, S. M. (2004) Effect of linker sequences between the antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody. Protein Eng. Des. Sel. 17, 357–366.
Cochlovius, B., Kipriyanov, S. M., Stassar, M. J., Schuhmacher, J., Benner, A., Moldenhauer, G., and Little, M. (2000) Cure of Burkitt’s lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3 x CD19 tandem diabody, and CD28 costimulation. Cancer Res. 60, 4336–4341.
Reusch, U., Le Gall, F., Hensel, M., Moldenhauer, G., Ho, A. D., Little, M., and Kipriyanov, S. M. (2004) Effect of tetravalent bispecific CD19 x CD3 recombinant antibody construct and CD28 costimulation on lysis of malignant B cells from patients with chronic lymphocytic leukemia by autologous T cells. Int. J. Cancer 112, 509–518.
De Jonge, J., Heirman, C., de Veerman, M., Van Meirvenne, S., Moser, M., Leo, O., and Thielemans, K. (1998) In vivo retargeting of T cell effector function by recombinant bispecific single chain Fv (anti-CD3 x anti-idiotype) induces long-term survival in the murine BCL1 lymphoma model. J. Immunol. 161, 1454–1461.
Little, M., and Kipriyanov, S. (2007) Flawed TandAb production. Mol. Immunol. 44, 3083.
Kipriyanov, S. M., Moldenhauer, G., and Little, M. (1997) High level production of soluble single chain antibodies in small-scale Escherichia coli cultures. J. Immunol. Methods 200, 69–77.
Bothmann, H., and Plückthun, A. (1998) Selection for a periplasmic factor improving phage display and functional periplasmic expression. Nat. Biotechnol. 16, 376–380.
Bothmann, H., and Plückthun, A. (2000) The periplasmic Escherichia coli peptidylprolyl cis,trans-isomerase FkpA. I. Increased functional expression of antibody fragments with and without cis-prolines. J. Biol. Chem. 275, 17100–17105.
Ramm, K., and Plückthun, A. (2000) The periplasmic Escherichia coli peptidylprolyl cis,trans-isomerase FkpA. II. Isomerase-independent chaperone activity in vitro. J. Biol. Chem. 275, 17106–17113.
Ramm, K., and Plückthun, A. (2001) High enzymatic activity and chaperone function are mechanistically related features of the dimeric E. coli peptidyl-prolyl-isomerase FkpA. J. Mol. Biol. 310, 485–498.
Maurer, R., Meyer, B., and Ptashne, M. (1980) Gene regulation at the right operator (OR) bacteriophage lambda. I. OR3 and autogenous negative control by repressor. J. Mol. Biol. 139, 147–161.
Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
Kipriyanov, S. M., Moldenhauer, G., Martin, A. C., Kupriyanova, O. A., and Little, M. (1997) Two amino acid mutations in an anti-human CD3 single chain Fv antibody fragment that affect the yield on bacterial secretion but not the affinity. Protein Eng. 10, 445–453.
Laemmli, U. K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680–685.
Horn, U., Strittmatter, W., Krebber, A., Knupfer, U., Kujau, M., Wenderoth, R., Müller, K., Matzku, S., Plückthun, A., and Riesenberg, D. (1996) High volumetric yields of functional dimeric miniantibodies in Escherichia coli, using an optimized expression vector and high-cell-density fermentation under non-limited growth conditions. Appl. Microbiol. Biotechnol. 46, 524–532.
Le Gall, F., Reusch, U., Moldenhauer, G., Little, M., and Kipriyanov, S. M. (2004) Immunosuppressive properties of anti-CD3 single-chain Fv and diabody. J. Immunol. Methods 285, 111–127.
Casey, J. L., Keep, P. A., Chester, K. A., Robson, L., Hawkins, R. E., and Begent, R. H. (1995) Purification of bacterially expressed single chain Fv antibodies for clinical applications using metal chelate chromatography. J. Immunol. Methods 179, 105–116.
Bradford, M. M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248–254.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Humana Press, a part of Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Kipriyanov, S.M. (2009). Generation of Bispecific and Tandem Diabodies. In: Aitken, R. (eds) Antibody Phage Display. Methods in Molecular Biology, vol 562. Humana Press. https://doi.org/10.1007/978-1-60327-302-2_14
Download citation
DOI: https://doi.org/10.1007/978-1-60327-302-2_14
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-60327-301-5
Online ISBN: 978-1-60327-302-2
eBook Packages: Springer Protocols